Contingent Value Rights in Life Sciences Transactions

Contingent value rights (CVRs) represent an increasingly prominent part of the M&A landscape in the life sciences industry. Please join Ropes & Gray attorneys Paul Kinsella and Marko Zatylny as they discuss the use of CVRs to address uncertainties inherent in the development and commercialization of pharmaceutical products, bridge valuation gaps, and facilitate negotiations. They also will provide an overview of the common CVR features and legal and contractual issues arising out of the use of CVRs.
Cookie Settings